Trading Outlook for Peregrine Pharmaceuticals Issued by

DALLAS, Oct. 26, 2009 (GLOBE NEWSWIRE) -- announces an investment report featuring anti-cancer and antiviral drug developer Peregrine Pharmaceuticals (Nasdaq:PPHMD). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.

The investment report on Peregrine Pharmaceuticals (Nasdaq:PPHMD) should be of particular interest to other biopharmaceutical companies: SuperGen Inc. (Nasdaq:SUPG), Human Genome Sciences (Nasdaq:HGSI), Amgen Inc. (Nasdaq:AMGN) and Schering-Plough Corp. (NYSE:SGP).

The full report is available at:

Get our alerts BEFORE the rest of the market. Follow us on Twitter:

Peregrine Pharmaceuticals (PPHMD), a clinical-stage biopharmaceutical company, engages in the manufacture and development of monoclonal antibodies for the treatment of cancer and viral infections. Its drug development pipeline consists of novel compounds bavituximab and Cotara, with which the Company pursues in three separate clinical programs in cancer and hepatitis C virus (HCV) infection. On October 21, the Company reported that bavituximab, in combination with Sanofi-Aventis' chemotherapy drug Taxotere, prompted an improvement in response rates in advanced breast cancer patients during a midstage clinical trial. The Company, through its wholly owned subsidiary Avid Bioservices Inc., also provides contract manufacturing services for biotechnology and biopharmaceutical companies, from pre-clinical drug supplies up through commercial-scale drug manufacture.

In the report, the analyst notes:

"On October 21, the Company announced positive results from its phase II trial evaluating bavituximab in combination with Taxotere, also known as docetaxel, in patients with advanced breast cancer. According to the Company, preliminary data at the end of the six planned treatment cycles in the phase II study showed that 28 of 46, or 61%, of all patients enrolled in the trial achieved an objective tumor response according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria."

"PPHMD's advancements in its bavituximab and Cotara cancer clinical trials, which are considered to be key value drivers for the Company, have continued into fiscal year 2010. Lead drug bavituximab is stepping towards clearance in phase III trials, which should give the Company a significant boost. While the Company continues to move its drug prospects forward, it expects its new capital structure to attract a broader range of investors to the Company."

To read the entire report visit: is a small-cap research and investment commentary provider striving to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: Disclosure is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. is a Web site wholly owned by BlueWave Advisors, LLC. Please read our report and visit our Web site,, for complete risks and disclosures.

          Jeff Bishop

Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here